In this issue:
NRAS, not KRAS, mutation reduces sensitivity to bortezomib
DUB inhibitor overcomes bortezomib resistance in MM
Lenalidomide’s effects on Ikaros proteins
Clinical features and outcomes of IgD myeloma in the novel agent era
MicroRNAs as biomarkers in MM and MGUS
Allele-specific oligonucleotide real-time quantitative PCR for
MRD evaluation
Prophylaxis against VZV, and complicated VZV/HSV, in
lenalidomide-treated MM
Consolidation/maintenance with RVD in high-risk MM
Impact of failed novel agent
induction in MM post-ASCT
Please login below to download this issue (PDF)